TelyRx Holdings Inc. is making waves on the TSX with a significant surge in stock price.
TelyRx Holdings Inc. (TELY.TO) is rising today, gaining an impressive 8.70% to close at CA$2.50. This upward movement reflects growing investor confidence in the company's recent performance and strategic developments.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
TelyRx Holdings Inc.
TELY.TO
TELY.TO
TelyRx Holdings Inc.
WealthAwesomeMarket cap
$74.42M
52W high
$4.25
52W low
$2.00
1W change
-17.86%
Analyst Price Targets
Based on analyst covering TELY
Wall Street analysts forecast TELY stock price to rise 160.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+160.9% Upside
Current Price
C$2.30
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TELY's historical volatility
30-Day Vol
99.7%
Annualized
90-Day Vol
100.3%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.92
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.17 | C$1.54 – C$3.06 |
| 60 trading days | C$2.04 | C$1.26 – C$3.32 |
| 90 trading days | C$1.92 | C$1.06 – C$3.49 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should consider TelyRx's recent revenue growth and market positioning as potential indicators of future performance.
TelyRx Holdings Inc. sees an 8.70% increase in stock price today.
The stock's rise today brings TelyRx's market cap to CA$74.42 million, indicating a positive market response to its recent performance metrics.
Bull case
In Q1 2026, TelyRx reported a notable revenue increase, climbing to CA$19.4 million. This is a significant jump compared to both the previous quarter and the same quarter last year. The growth, along with a rising number of prescriptions filled, suggests that the company is strengthening its market presence.
Bear case
Despite the positive revenue growth, TelyRx is still operating at a loss, with a net loss of CA$4.7 million in Q1 2026. Investors should remain cautious as the company navigates its financial challenges.
Recent Performance Highlights
Advertisement
TelyRx's stock has surged by 8.70% today, closing at CA$2.50. This performance follows the company's announcement of a revenue increase to CA$19.4 million in Q1 2026, showcasing a robust growth trajectory compared to prior periods.
Financial Overview
While TelyRx reported impressive revenue growth, it also faced a net loss of CA$4.7 million in the same quarter. Investors should weigh the potential for future growth against the backdrop of ongoing financial challenges. For more insights, check out the full financial results.
Market Sentiment
The market's positive reaction today suggests that investors are optimistic about TelyRx's future, particularly in light of its increasing prescription volumes and strategic developments. For a deeper dive into the stock's performance, visit our TelyRx stock page.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
